ARTICLE | Emerging Company Profile
RayzeBio pulling together radiotherapy platform with $45 million
RayzeBio combines the tumor-killing of actinium 225 with the target affinity and PK of macrocycles
October 15, 2020 1:02 AM UTC
RayzeBio thinks its targeting and radioisotope strategies can take radiopharmaceuticals from a series of individual success stories to a broadly applicable platform technology for cancer.
The company made its debut Wednesday with a $45 million series A round co-led by venBio Partners and Versant Ventures, with participation from Samsara BioCapital...